Editorial
1953 Classification and diagnostic criteria in Sjögren’s syndrome: a long-standing and still open controversy
C Vitali, N Del Papa

Criteria
1955 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

Recommendations
1965 European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative

1974 The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology

Clinical and epidemiological research
1980 Comparison of the performance of the 1965 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients

1986 Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
P Emery, J Vencovsky, A Sywestrak, P Leszczyński, W Pozawska, B Stasiak, J Hilt, Z Mosterova, S Y Cheong, J Ghol

1992 Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece

2001 Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
Takesaki, C Thorne, G Karpouzas, S Sheng, W Xu, R Rao, K Fei, B Hsu, P P Tak

2009 Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
M G Tektonidou, I E Lewandowski, J Hu, A Dasgupta, M M Ward

2017 Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis
A Maniel, A Holmqvist, T Jernberg, S Wällberg-Jonsson, J Aekling

2025 Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
Basic and translational research

2031 Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

2038 The effects of structural damage on functional disability in psoriatic arthritis
A Kerschenbaumer, D Baker, J S Smolen, D Aletaha

2046 Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand

2054 Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort
C. Gaujoux-Viala, N Rincheval, M Dougdos, B Combe, B Faure

2061 Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
S T Kim, J Taya, V A Trimb, M Suarez-Almazor, S Garcia, P Hwu, D H Johnson, D H Johnson, M Vemor, A Dab

2065 Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study
I K Stamp, P T Chapman, M Barclay, A Horne, C Frampton, P T Lai, J Drake, N Dalbeth

2071 Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multithenic, multinational Latin American Lupus Cohort (GLADEL)

2085 A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever

2095 B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis
A Cortini, U Ellinghaus, T H Malik, D S Connningshane, M Bett, T J Vyse

2105 Identification of a transitional fibroblast function in very early rheumatoid arthritis
A Feri, L S C Ward, S Kemble, C S Davies, H Munt, R Rogers, K Zappa, C D Buckley, G B Nash, H M McGett

Correction
2103 Erratum: Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts

Electronic pages

Correspondence
e49 Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis
I Pirila, T Sokka, M J Kauppi, V M Rantalaaho, E Mervaala, K Paalakk

e50 Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirilä et al
J F Smolen, R B M Landewé, D van der Heijde

e51 HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study
J Bluett, S A Owen, J Massey, A Alfieie, M Pirmohamed, D Plant, S M M Vrmary, A Barton, on behalf of The Pneumonitis Study Consortium

e52 Response to: 'HLA-A* 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome wide association study’ by Bluett et al
H Farukawa, S Oka, K Shimada, N Tsuchiya, S Toba, on behalf of the Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) Study Consortium

e53 EULAR recommendations underplay importance of severe anxiety and depression in fibromyalgia treatment
C. Mercieca, A A Borg

e54 EULAR recommendations for management of fibromyalgia